% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wankhede:282508,
      author       = {D. Wankhede$^*$ and S. Grover and P. Hofman},
      title        = {{T}he prognostic value of {TMB} in early-stage non-small
                      cell lung cancer: a systematic review and meta-analysis.},
      journal      = {Therapeutic advances in medical oncology},
      volume       = {15},
      issn         = {1758-8340},
      address      = {Thousand Oaks, Calif.},
      publisher    = {Sage},
      reportid     = {DKFZ-2023-01797},
      pages        = {17588359231195199},
      year         = {2023},
      note         = {#EA:C070#},
      abstract     = {Tumor mutation burden (TMB) has been validated as a
                      predictive biomarker for immunotherapy response and survival
                      in numerous cancer types. Limited data is available on the
                      inherent prognostic role of TMB in early-stage tumors.To
                      evaluate the prognostic role of TMB in early-stage, resected
                      non-small cell lung cancer (NSCLC).Systematic review and
                      meta-analysis of pertinent prospective and retrospective
                      studies.Publication search was performed in PubMed, Embase,
                      Cochrane Library, and Web of Science databases. Based on the
                      level of heterogeneity, a random- or fixed-effects model was
                      used to calculate pooled effects of hazard ratio (HR) for
                      overall survival (OS) and disease-free survival (DFS). The
                      source of heterogeneity was investigated using sensitivity
                      analysis, subgroup analysis, and publication bias
                      assessment.Ten studies comprising 2520 patients were
                      included in this analysis. There was no statistically
                      significant difference in OS (HR, 1.18, $95\%$ CI, 0.70,
                      1.33; p 0.53, I2 = $80\%;$ phet < 0.0001) and DFS (HR, 1.18,
                      $95\%$ CI, 0.91, 1.52; p = 0.53, I2 = $75\%;$ phet = 0.0001)
                      between the high-TMB and low-TMB group. Subgroup analyses
                      indicated that East Asian ethnicity, and TMB detected using
                      whole exome sequencing, and studies with <100 patients had
                      poor DFS in the high-TMB group.The inherent prognostic role
                      of TMB is limited in early-stage NSCLC. Ethnic differences
                      in mutation burden must be considered while designing future
                      trials on neoadjuvant immunotherapy. Further research in the
                      harmonization and standardization of panel-based TMB is
                      essential for its widespread clinical utility.Registration:
                      CRD42023392846.},
      keywords     = {disease-free survival (Other) / meta-analysis (Other) /
                      non-small cell lung cancer (Other) / overall survival
                      (Other) / tumor mutation burden (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37667779},
      pmc          = {pmc:PMC10475237},
      doi          = {10.1177/17588359231195199},
      url          = {https://inrepo02.dkfz.de/record/282508},
}